CL2020002563A1 - Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b - Google Patents

Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b

Info

Publication number
CL2020002563A1
CL2020002563A1 CL2020002563A CL2020002563A CL2020002563A1 CL 2020002563 A1 CL2020002563 A1 CL 2020002563A1 CL 2020002563 A CL2020002563 A CL 2020002563A CL 2020002563 A CL2020002563 A CL 2020002563A CL 2020002563 A1 CL2020002563 A1 CL 2020002563A1
Authority
CL
Chile
Prior art keywords
fubp1
treatment
hepatitis
virus infection
relates
Prior art date
Application number
CL2020002563A
Other languages
English (en)
Inventor
Søren Ottosen
Lykke Pedersen
Souphalone Luangsay
Barbara Testoni
Fabien Zoulim
Original Assignee
Hoffmann La Roche
Centre Leon Berard
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Centre Leon Berard filed Critical Hoffmann La Roche
Publication of CL2020002563A1 publication Critical patent/CL2020002563A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Abstract

La presente invención se relaciona con un inhibidor de FUBP1 para uso en el tratamiento de una infección de HBV, en particular una infección de HBV crónica. La invención en particular se relaciona con el uso de inhibidores de FUBP1 para desestabilizar ADNccc, tal como ADNccc de HBV. La invención también se relaciona con moléculas de ácido nucleico, tales como oligonucleótidos incluyendo ARNip, ARNhc y oligonucleótidos anti sentido, que son complementarios a FUBP1 y capaces de reducir el ARNm de FUBP1. También comprendida en la presente invención es una composición farmacéutica y su uso en el tratamiento y/o la prevención de una infección de HBV.
CL2020002563A 2018-04-05 2020-10-02 Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b CL2020002563A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18165897 2018-04-05

Publications (1)

Publication Number Publication Date
CL2020002563A1 true CL2020002563A1 (es) 2021-05-07

Family

ID=61911421

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002563A CL2020002563A1 (es) 2018-04-05 2020-10-02 Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b

Country Status (18)

Country Link
US (1) US11732262B2 (es)
EP (1) EP3775208A1 (es)
JP (1) JP2021520387A (es)
KR (1) KR20200140853A (es)
CN (1) CN112055749A (es)
AU (1) AU2019247645A1 (es)
BR (1) BR112020020220A8 (es)
CA (1) CA3097544A1 (es)
CL (1) CL2020002563A1 (es)
CR (1) CR20200453A (es)
IL (1) IL277745A (es)
MA (1) MA52661A (es)
MX (1) MX2020010383A (es)
PE (1) PE20211912A1 (es)
RU (1) RU2020135289A (es)
SG (1) SG11202009680XA (es)
TW (1) TW202006138A (es)
WO (1) WO2019193165A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010383A (es) 2018-04-05 2020-12-10 Hoffmann La Roche Uso de inhibidores de fubp1 para el tratamiento de infeccion de virus de hepatitis b.
JP2023506540A (ja) * 2019-12-19 2023-02-16 エフ． ホフマン－ラ ロシュ エージー． Ｂ型肝炎ウイルス感染を処置するためのｓｃａｍｐ３阻害剤の使用
AR122731A1 (es) 2020-06-26 2022-10-05 Hoffmann La Roche Oligonucleótidos mejorados para modular la expresión de fubp1
EP4200419A2 (en) * 2020-08-21 2023-06-28 F. Hoffmann-La Roche AG Use of a1cf inhibitors for treating hepatitis b virus infection
WO2023111210A1 (en) 2021-12-17 2023-06-22 F. Hoffmann-La Roche Ag Combination of oligonucleotides for modulating rtel1 and fubp1
CN115851725A (zh) * 2022-10-28 2023-03-28 珠海市人民医院 一种抑制解螺旋酶Ⅴ基因表达的siRNA及其应用

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE239484T1 (de) 1991-10-24 2003-05-15 Isis Pharmaceuticals Inc Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen
US5580760A (en) * 1993-02-22 1996-12-03 The United States Of America As Represented By The Department Of Health And Human Services FUSE binding protein and cDNA therefor
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
IL135000A0 (en) 1997-09-12 2001-05-20 Exiqon As Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues
EP1152009B2 (en) 1999-02-12 2017-09-06 Daiichi Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
KR100782896B1 (ko) 1999-05-04 2007-12-06 엑시콘 에이/에스 Ｌ-리보-ｌｎａ 유사체
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
AU2003296897A1 (en) 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
WO2004027061A1 (ja) 2002-09-17 2004-04-01 Yamanouchi Pharmaceutical Co., Ltd. 抗増殖性疾患治療薬のスクリーニング方法
DK2284269T3 (en) 2002-11-18 2017-10-23 Roche Innovation Ct Copenhagen As Antisense design
SI2270162T1 (sl) 2003-06-12 2019-03-29 Alnylam Pharmaceuticals Inc. Konzervirana HBV in HCV zaporedja uporabna za utišanje genov
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
WO2006082053A1 (en) 2005-02-02 2006-08-10 Heidelberg Pharma Gmbh 7-ethyl-10-hydroxy-camptothecin lipid ester derivatives
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
KR20130042043A (ko) 2006-01-27 2013-04-25 아이시스 파마수티컬즈 인코포레이티드 6-변형된 바이시클릭 핵산 유사체
US20090326042A1 (en) 2006-05-05 2009-12-31 Isis Pharmaceuticals, Inc Compounds and methods for modulating expression of crp
DK2066684T3 (da) 2006-05-11 2012-10-22 Isis Pharmaceuticals Inc 5´-Modificerede bicycliske nukleinsyreanaloge
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
US8580756B2 (en) 2007-03-22 2013-11-12 Santaris Pharma A/S Short oligomer antagonist compounds for the modulation of target mRNA
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
WO2009006478A2 (en) 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US8546556B2 (en) 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
KR20110110776A (ko) 2008-12-18 2011-10-07 다이서나 파마수이티컬, 인크. 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법
WO2010093788A2 (en) 2009-02-11 2010-08-19 Dicerna Pharmaceuticals, Inc. Multiplex dicer substrate rna interference molecules having joining sequences
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
KR20120095397A (ko) 2009-10-16 2012-08-28 글락소 그룹 리미티드 Ｈｂｖ 안티센스 억제제
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2012024170A2 (en) 2010-08-17 2012-02-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
DK3124610T3 (da) 2010-10-28 2019-06-11 Benitec Biopharma Ltd Hbv-behandling
JP2014514313A (ja) 2011-04-20 2014-06-19 ロシュ グリクアート アクチェンゲゼルシャフト 血液脳関門のｐＨ依存性通過のための方法及び構築物
CN111172162A (zh) 2011-04-21 2020-05-19 葛兰素史克公司 乙型肝炎病毒(hbv)表达的调节
SG194751A1 (en) 2011-06-30 2013-12-30 Arrowhead Res Corp Compositions and methods for inhibiting gene expression of hepatitis b virus
US10202599B2 (en) 2011-08-11 2019-02-12 Ionis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US10023861B2 (en) 2011-08-29 2018-07-17 Ionis Pharmaceuticals, Inc. Oligomer-conjugate complexes and their use
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
WO2013159109A1 (en) 2012-04-20 2013-10-24 Isis Pharmaceuticals, Inc. Modulation of hepatitis b virus (hbv) expression
US20150291958A1 (en) 2012-11-15 2015-10-15 Roche Innovation Center Copenhagen A/S Anti apob antisense conjugate compounds
FR2998748B1 (fr) 2012-11-23 2015-04-10 Commissariat Energie Atomique Dispositif et procede de retransmission de donnees dans un commutateur reseau
AU2014259759B2 (en) 2013-05-01 2020-06-18 Ionis Pharmaceuticals, Inc. Compositions and methods
EP3591054A1 (en) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Antisense oligomers and conjugates targeting pcsk9
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
JP2017536092A (ja) * 2014-10-02 2017-12-07 プロティバ バイオセラピューティクス インコーポレイテッド Ｂ型肝炎ウイルスの遺伝子発現をサイレンシングするための組成物及び方法
KR20170068469A (ko) 2014-10-10 2017-06-19 에프. 호프만-라 로슈 아게 ＧａｌＮＡｃ 포스포라미다이트, 그의 핵산 컨쥬게이트 및 그의 용도
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
WO2016100975A1 (en) * 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
CN105777770B (zh) 2014-12-26 2018-05-25 中国人民解放军第二军医大学 一种饱和长链脂肪酸修饰的7-乙基-10-羟基喜树碱化合物及其长循环脂质体
US20180023081A1 (en) 2015-02-04 2018-01-25 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
EP3325097B1 (en) 2015-07-17 2021-09-01 Arcturus Therapeutics, Inc. Compositions and agents against hepatitis b virus and uses thereof
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
CN109153697A (zh) 2016-04-14 2019-01-04 豪夫迈·罗氏有限公司 三苯甲基-单-GalNAc化合物及其用途
MA45496A (fr) 2016-06-17 2019-04-24 Hoffmann La Roche Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
MX2020010383A (es) 2018-04-05 2020-12-10 Hoffmann La Roche Uso de inhibidores de fubp1 para el tratamiento de infeccion de virus de hepatitis b.

Also Published As

Publication number Publication date
CR20200453A (es) 2021-03-02
SG11202009680XA (en) 2020-10-29
US20210024934A1 (en) 2021-01-28
MA52661A (fr) 2021-02-17
US11732262B2 (en) 2023-08-22
AU2019247645A1 (en) 2020-10-15
CA3097544A1 (en) 2019-10-10
CN112055749A (zh) 2020-12-08
TW202006138A (zh) 2020-02-01
PE20211912A1 (es) 2021-09-28
JP2021520387A (ja) 2021-08-19
MX2020010383A (es) 2020-12-10
BR112020020220A2 (pt) 2021-01-19
RU2020135289A (ru) 2022-05-05
EP3775208A1 (en) 2021-02-17
IL277745A (en) 2020-11-30
WO2019193165A1 (en) 2019-10-10
KR20200140853A (ko) 2020-12-16
BR112020020220A8 (pt) 2021-02-17

Similar Documents

Publication Publication Date Title
CL2020002563A1 (es) Uso de inhibidores de fubp1 para el tratamiento de infección de virus de hepatitis b
PE20190443A1 (es) Moleculas de acido nucleico para la reduccion de arnm de papd5 o papd7 para tratar la infeccion por hepatitis b
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
BR112019002117A2 (pt) agente de rnai contra infecção do vírus da hepatite b
MX2021006635A (es) Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas.
BR112018009009A8 (pt) terapia combinada de um inibidor de formação de capsídeo hbv e um interferon
WO2017027350A3 (en) Rnai therapy for hepatitis b virus infection
EA201792069A1 (ru) Производные азокана и азонана и способы лечения инфекций гепатита в
CR20190207A (es) MODULACIÓN DE LA EXPRESIÓN DEL VIRUS DE LA HEPATITIS B (VHB) (Divisional 2013-0551)
BR112019004560A2 (pt) tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
PH12017500010A1 (en) Methods for the treatment of hepatitis b and hepatitis d virus infections
CO2020001354A2 (es) Métodos y composiciones para tratar un evento de sangrado en un sujeto que padece hemofilia un arni, por ejemplo, un ácido ribonucleico de hebra doble (arnhd), composiciones dirigidas al gen serpinc1 y métodos para usar dicho arni, por ejemplo, arnhd, composiciones para tratar un evento de sangrado en un sujeto que tiene una hemofilia (por ejemplo, con o sin inhibidores).
BR112017018329A2 (pt) composição para prevenir ou tratar calcificação de válvula, contendo inibidor de dpp-4
MX2020003464A (es) Molecula de acidos nucleicos para la reduccion del arnm de papd5 y papd7 en el tratamiento de la infeccion de la hepatitis b.
AR114551A1 (es) COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO
CL2021000018A1 (es) Oligonucleótidos para modular la expresión de rtel1
CL2020001638A1 (es) Molécula de ácidos nucleicos para la reducción del arnm de papd5 y papd7 en el tratamiento de la infección de la hepatitis b. (divisional solicitud 202000945)
CO2023000116A2 (es) Oligonucleótidos mejorados para modular la expresión de fubp1
PH12018502320A1 (en) Reagents for treatment of hepatitis b virus (hbv) infection and use thereof
WO2021122921A8 (en) Use of cops3 inhibitors for treating hepatitis b virus infection
AR113771A1 (es) Molécula de ácidos nucleicos para la reducción del arnm de papd5 y papd7 en el tratamiento de la infección de la hepatitis b
EA202191771A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ RNAi ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
AR105611A1 (es) TERAPIA ARNi PARA INFECCIÓN POR VIRUS DE HEPATITIS B
AR111410A1 (es) Combinación sinérgica de oligonucleótidos de ácidos nucleicos y agentes quimioterapéuticos inhibidores de proteína quinasas
MA40218A (fr) Procédés pour le traitement d'infections par le virus de l'hépatite b et le virus de l'hépatite d